Articles related to CLINICAL TRIALS

The study demonstrates that tirzepatide significantly reduces apnea–hypopnea index and body weight in patients with obstructive sleep apnea and obesity, indicating its potential role in improving both sleep and metabolic health.

In a phase 3 trial, the combination of amivantamab and lazertinib resulted in a median progression-free survival of 23.7 months, surpassing the 16.6 months observed with osimertinib in patients with EGFR-mutated advanced NSCLC.

In a recent study, 95% of ITP patients treated with the novel anti-CD38 monoclonal antibody, CM313, achieved two consecutive platelet counts of at least 50×10^9 per liter within just eight weeks, highlighting the therapy’s efficacy and rapid action.

A phase 2 trial found that tirzepatide, administered once weekly, significantly improved the resolution of MASH and fibrosis stages in patients with moderate to severe liver fibrosis. These results highlight tirzepatide’s potential as a treatment option, emphasizing the need for further research to validate these findings in larger, long-term studies.

The TROPiCs-04 trial results challenge the current treatment landscape for metastatic urothelial carcinoma, highlighting the need for new strategies post-relapse and the importance of next-generation sequencing in patient selection.

Pirtobrutinib offers a new line of therapy for CLL and SLL patients who have progressed after covalent BTK inhibitors and venetoclax, with a significant overall response rate and manageable adverse events.